Immunome spent $59.9 million on research and development in the six months ended June 30, up 48% from the comparable period. The product pipeline is getting more expensive to advance, and the business generated no revenue at all.
That would be a straightforward cash-burn story if the balance sheet had moved in the same direction. It did not. Cash rose from $143.9 million to $217.7 million, even as operating cash outflow widened from $102.5 million to $120.3 million. The filing does not say why cash increased.
The more important change is what Immunome is funding. Operating income fell to a $78.1 million loss from a $46.5 million loss, while diluted shares rose 30.2% to 113.3 million. More cash is available, but more ownership has been issued and more money is leaving the operating business.
Immunome describes the cost curve in clinical development plainly:
"For example, product candidates in later stages of clinical development generally have higher costs than those in earlier stages, primarily due to the size and cost of later-stage clinical trials compared to early development activities."
10-Q 2026-08-11
That gives the larger R&D bill a disclosed explanation. It also puts a boundary around the cash balance: the company is spending to move candidates through development, not reporting a commercial business that is already paying for the effort.
The revenue comparison is even starker. Immunome recorded $4.0 million in revenue in the first six months of 2025 and zero in the latest six-month period. The earlier revenue was tied to research and development work allocated to AbbVie:
"Collaboration revenue for the six months ended June 30, 2025 related to certain research and development activities allocated to AbbVie."
10-Q 2026-08-11
The company also says the absence of product sales may persist:
"Furthermore, we may not generate any revenue from product sales for the foreseeable future, and we expect to continue to incur significant operating losses for the foreseeable future due to the cost of research and development activities and the regulatory approval process for our programs and product candidates."
10-Q 2026-08-11
So the latest report is not simply a cash-rich biotech update. It is a report of a larger funding cushion alongside a business whose revenue disappeared, whose loss widened, and whose share count expanded. The market value was $2.3 billion at the latest annual facts, against $6.9 million of 2025 revenue, while the stock closed at $26.25 on August 11, up 2.3% that day and 170.9% over 12 months. Those are descriptions of scale and trading history, not explanations of the move.
The company has also warned that future funding may be needed for clinical trials, IND filings, commercialization efforts, and expanded research. Immunome's next 10-Q would answer the unresolved question: has AbbVie-related collaboration revenue returned, or is the company still financing a zero-revenue pipeline despite reporting no revenue in the period?